Trial Profile
Phase II Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cance
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 09 Jan 2016 New trial record